These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23535073)

  • 1. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
    Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
    J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
    Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
    Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
    Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
    Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
    Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
    Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
    Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
    Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF activates and physically interacts with PAK to regulate cell motility.
    McCarty SK; Saji M; Zhang X; Knippler CM; Kirschner LS; Fernandez S; Ringel MD
    Endocr Relat Cancer; 2014; 21(6):865-77. PubMed ID: 25228413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations.
    Smalley KS; Weber JS
    J Natl Cancer Inst; 2013 May; 105(9):591-2. PubMed ID: 23535072
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
    Ong CC; Jubb AM; Haverty PM; Zhou W; Tran V; Truong T; Turley H; O'Brien T; Vucic D; Harris AL; Belvin M; Friedman LS; Blackwood EM; Koeppen H; Hoeflich KP
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7177-82. PubMed ID: 21482786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
    Sharma A; Shah SR; Illum H; Dowell J
    Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
    Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
    PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
    Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
    Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.